Compare · CERS vs CTSH
CERS vs CTSH
Side-by-side comparison of Cerus Corporation (CERS) and Cognizant Technology Solutions Corporation (CTSH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CERS and CTSH operate in EDP Services (Technology), so they compete in similar markets.
- CTSH is the larger of the two at $44.35B, about 51.2x CERS ($866.5M).
- CTSH has been more active in the news (10 items in the past 4 weeks vs 4 for CERS).
- CTSH has more recent analyst coverage (25 ratings vs 3 for CERS).
- Company
- Cerus Corporation
- Cognizant Technology Solutions Corporation
- Price
- $1.98+4.49%
- $55.10-0.02%
- Market cap
- $866.5M
- $44.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- EDP Services
- EDP Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1997
- 1998
- News (4w)
- 4
- 10
- Recent ratings
- 3
- 25
Cerus Corporation
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation has collaboration with LifeSouth Community Blood Centers to manufacture INTERCEPT Fibrinogen Complex. The company was incorporated in 1991 and is headquartered in Concord, California.
Cognizant Technology Solutions Corporation
Cognizant Technology Solutions Corporation, a professional services company, provides consulting and technology, and outsourcing services in North America, Europe, and internationally. The company operates through four segments: Financial Services; Healthcare; Products and Resources; and Communications, Media and Technology. It offers customer experience enhancement, robotic process automation, analytics, and AI services in areas, such as digital lending, fraud detection, and next generation payments; and enhanced compliance, integrated health management, claims investigative services, and patient experience, as well as services that drive operational improvements in areas, such as claims processing, enrollment, membership, and billing to healthcare providers and payers, and life sciences companies, including pharmaceutical, biotech, and medical device companies. The company also provides solution to manufacturers, retailers and travel and hospitality companies, as well as companies providing logistics, energy and utility services; and cloud, interactive, and IoT services to information, media and entertainment, and communications and technology companies. Cognizant Technology Solutions Corporation was founded in 1994 and is headquartered in Teaneck, New Jersey.
Latest CERS
- SEC Form DEFA14A filed by Cerus Corporation
- SEC Form DEF 14A filed by Cerus Corporation
- Cerus Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Cerus Corporation to Release First Quarter 2026 Financial Results on April 30, 2026
- SEC Form 4 filed by Green Kevin Dennis
- SEC Form 4 filed by Jensen Chrystal
- Amendment: SEC Form SCHEDULE 13G/A filed by Cerus Corporation
- Chief Legal Officer Jensen Chrystal sold $187,277 worth of shares (113,008 units at $1.66), decreasing direct ownership by 11% to 946,131 units (SEC Form 4)
- Chief Operating Officer Jayaraman Vivek K sold $273,769 worth of shares (165,200 units at $1.66), decreasing direct ownership by 9% to 1,747,674 units (SEC Form 4)
- President and CEO Greenman William Mariner sold $742,023 worth of shares (447,757 units at $1.66), decreasing direct ownership by 8% to 4,998,493 units (SEC Form 4)
Latest CTSH
- Belcan Honored for Commitment to U.S. Navy Reservists
- Cognizant AI Lab Earns Three New U.S. Patents, Totaling 65 U.S. Patents and 88 International Patents
- Cognizant and Google Cloud Bring Agentic AI to Retail's Most Critical Customer Moments with Gemini Enterprise
- Cognizant and OpenAI Partner to Reshape Enterprise Software Engineering with Codex
- Cognizant joins J.P. Morgan Payments Consultant Implementation Program
- Cognizant Propels AI Workforce Training with Cognizant Skillspring™: New Talent Transformation Platform Designed to Accelerate Clients' Workforce AI Readiness
- SEC Form DEF 14A filed by Cognizant Technology Solutions Corporation
- SEC Form DEFA14A filed by Cognizant Technology Solutions Corporation
- Wedbush initiated coverage on Cognizant Tech with a new price target
- Cognizant Schedules First Quarter 2026 Earnings Release and Conference Call